Raloxifene inhibits cloned Kv4.3 channels in an estrogen receptor-independent manner

Pflugers Archiv European Journal of Physiology

Volumn 467, Issue 8, 2015, Pages 1663-1676

  Chae, Yun Ju ^a   Kim, Dae Hun ^a   Lee, Hong Joon ^a   Sung, Ki Wug ^a   Kwon, Oh Joo ^a   Hahn, Sang June ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Estrogen receptor; Kv4.3; Raloxifene; RT PCR

Indexed keywords

DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; POTASSIUM CHANNEL KV4.3; RALOXIFENE; RALOXIFENE 4' GLUCURONIDE; RALOXIFENE 6' GLUCURONIDE; TAMOXIFEN; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; ANTIESTROGEN; BONE DENSITY CONSERVATION AGENT; KV CHANNEL INTERACTING PROTEIN; MESSENGER RNA; POTASSIUM CHANNEL BLOCKING AGENT; SHAL POTASSIUM CHANNEL;

ACTIVATION TIME CONSTANT; ANIMAL CELL; ARTICLE; CHO CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DRUG MECHANISM; FEMALE; GLUCURONIDATION; IC50; LONG TERM EXPOSURE; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STEADY STATE; TIME-DEPENDENT INHIBITION; WHOLE CELL PATCH CLAMP; ANIMAL; ANTAGONISTS AND INHIBITORS; CHANNEL GATING; CRICETULUS; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; KINETICS; METABOLISM; MOLECULAR CLONING; PATCH CLAMP TECHNIQUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CHO CELLS; CLONING, MOLECULAR; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ION CHANNEL GATING; KINETICS; KV CHANNEL-INTERACTING PROTEINS; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; RALOXIFENE HYDROCHLORIDE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SHAL POTASSIUM CHANNELS; TAMOXIFEN; TRANSFECTION;

EID: 84937809897     PISSN: 00316768     EISSN: 14322013     Source Type: Journal    
DOI: 10.1007/s00424-014-1602-3     Document Type: Article

References (57)

1. + channels, Kv1.5 and Kv3.1, by riluzole. Neuroscience 133:1007–19
2. Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, Jo YH, Kim MS, Sung KW, Hahn SJ (2006) Interaction of riluzole with the closed inactivated state of Kv4.3 channels. J Pharmacol Exp Ther 319:323–31
3. Beck EJ, Bowlby M, An WF, Rhodes KJ, Covarrubias M (2002) Remodelling inactivation gating of Kv4 channels by KChIP1, a small-molecular-weight calcium-binding protein. J Physiol 538:691–706
4. Beck EJ, Covarrubias M (2001) Kv4 channels exhibit modulation of closed-state inactivation in inside-out patches. Biophys J 81:867–83
5. Bett GC, Morales MJ, Strauss HC, Rasmusson RL (2006) KChIP2b modulates the affinity and use-dependent block of Kv4.3 by nifedipine. Biochem Biophys Res Commun 340:1167–77
6. Birnbaum SG, Varga AW, Yuan LL, Anderson AE, Sweatt JD, Schrader LA (2004) Structure and function of Kv4-family transient potassium channels. Physiol Rev 84:803–33
7. Bryant HU, Glasebrook AL, Yang NN, Sato M (1999) An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 69:37–44
8. Butterworth JF, Strichartz GR (1990) Molecular mechanisms of local anesthesia: a review. Anesthesiology 72:711–34
9. Chung MT, Cheng PY, Lam KK, Chen SY, Ting YF, Yen MH, Lee YM (2010) Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats. Menopause 17:127–34
10. Delpon E, Valenzuela C, Gay P, Franqueza L, Snyders DJ, Tamargo J (1997) Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 35:341–50
11. + channel behaves like an open-channel blocker. Neuron 7:743–53
12. + channel in ventricular muscle. A molecular correlate for the transient outward current. Circ Res 79:659–68
13. Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, Spangle LA, Martin MJ, Phillips DL, Glasebrook AL, Osborne JJ, Frolik CA, Bryant HU (1997) Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol 61:97–106
14. Eghbali M, Deva R, Alioua A, Minosyan TY, Ruan H, Wang Y, Toro L, Stefani E (2005) Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 96:1208–16
15. Eghbali M, Wang Y, Toro L, Stefani E (2006) Heart hypertrophy during pregnancy: a better functioning heart? Trends Cardiovasc Med 16:285–91
16. Feng J, Wang Z, Li GR, Nattel S (1997) Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 281:384–92
17. Grammer JB, Bosch RF, Kuhlkamp V, Seipel L (2000) Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation. J Cardiovasc Electrophysiol 11:626–33
18. Heringa M (2003) Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 41:331–45
19. James AF, Choisy SC, Hancox JC (2007) Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol 94:265–319
20. Jeong I, Choi BH, Hahn SJ (2011) Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation. Br J Pharmacol 163:510–20
21. Jeong EJ, Liu Y, Lin H, Hu M (2005) Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785–94
22. Kaab S, Dixon J, Duc J, Ashen D, Nabauer M, Beuckelmann DJ, Steinbeck G, McKinnon D, Tomaselli GF (1998) Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 98:1383–93
23. Kemp DC, Fan PW, Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694–700
24. Liew R, Stagg MA, MacLeod KT, Collins P (2004) Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current. Br J Pharmacol 142:89–96
25. Liu H, Jin MW, Xiang JZ, Huang Y, Sun HY, Chiu SW, Lau CP, Li GR (2007) Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. Eur J Pharmacol 563:61–8
26. Liu H, Yang L, Jin MW, Sun HY, Huang Y, Li GR (2010) The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation. Pharmacol Res 62:384–90
27. Mitchner NA, Harris ST (2009) Current and emerging therapies for osteoporosis. J Fam Pract 58:S45–9
28. Muchmore DB (2000) Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5:388–92
29. to) expression and regulation. J Mol Cell Cardiol 48:12–25
30. Ogita H, Node K, Asanuma H, Sanada S, Kim J, Takashima S, Minamino T, Hori M, Kitakaze M (2004) Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway. J Cardiovasc Pharmacol 43:821–9
31. Ogita H, Node K, Asanuma H, Sanada S, Liao Y, Takashima S, Asakura M, Mori H, Shinozaki Y, Hori M, Kitakaze M (2002) Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Am Coll Cardiol 40:998–1005
32. + channel α-subunit, Kv4.3 in the rat. FEBS Lett 420:47–53
33. Patel SP, Parai R, Campbell DL (2004) Regulation of Kv4.3 voltage-dependent gating kinetics by KChIP2 isoforms. J Physiol 557:19–41
34. Radicke S, Riedel T, Cotella D, Turnow K, Ravens U, Schaefer M, Wettwer E (2013) Accessory subunits alter the temperature sensitivity of Kv4.3 channel complexes. J Mol Cell Cardiol 56:8–18
35. Recker RR, Mitlak BH, Ni X, Krege JH (2011) Long-term raloxifene for postmenopausal osteoporosis. Curr Med Res Opin 27:1755–61
36. to). J Physiol 546:5–18
37. Saito T, Ciobotaru A, Bopassa JC, Toro L, Stefani E, Eghbali M (2009) Estrogen contributes to gender differences in mouse ventricular repolarization. Circ Res 105:343–52
38. Saitta A, Morabito N, Frisina N, Cucinotte D, Corrado F, D’Anna R, Altavilla D, Squadrito G, Minutoli L, Arcoraci V, Cancellieri F, Squadrito F (2001) Cardiovascular effects of raloxifene hydrochloride. Cardiovasc Drug Rev 19:57–74
39. Singleton CB, Valenzuela SM, Walker BD, Tie H, Wyse KR, Bursill JA, Qiu MR, Breit SN, Campbell TJ (1999) Blockade by N-3 polyunsaturated fatty acid of the Kv4.3 current stably expressed in Chinese hamster ovary cells. Br J Pharmacol 127:941–8
40. Snyder KR, Sparano N, Malinowski JM (2000) Raloxifene hydrochloride. Am J Health Syst Pharm 57:1669–75, quiz 1676–8
41. Snyders DJ (1999) Structure and function of cardiac potassium channels. Cardiovasc Res 42:377–90
42. Snyders DJ, Tamkun MM, Bennett PB (1993) A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 101:513–43
43. Snyders DJ, Yeola SW (1995) Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv1.5 channel. Circ Res 77:575–83
44. Song M, Helguera G, Eghbali M, Zhu N, Zarei MM, Olcese R, Toro L, Stefani E (2001) Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. J Biol Chem 276:31883–90
45. Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E (2004) Pharmacology of cardiac potassium channels. Cardiovasc Res 62:9–33
46. Thomas PB, Risinger KE, Klinge CM (2003) Identification of estrogen receptor beta expression in Chinese hamster ovary (CHO) cells and comparison of estrogen-responsive gene transcription in cells adapted to serum-free media. J Steroid Biochem Mol Biol 86:41–55
47. Thompson S (1982) Aminopyridine block of transient potassium current. J Gen Physiol 80:1–18
48. 2+ channels. Stroke 35:1709–14
49. Wang Z, Fermini B, Nattel S (1995) Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 272:184–96
50. 2+ channels in mouse spermatogenic cells. Pharmacology 87:70–80
51. Wang S, Patel SP, Qu Y, Hua P, Strauss HC, Morales MJ (2002) Kinetic properties of Kv4.3 and their modulation by KChIP2b. Biochem Biophys Res Commun 295:223–9
52. Wenger NK (2002) Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women. Diabetes Obes Metab 4:166–76
53. + channels. Ionic and gating current studies. J Gen Physiol 85:539–54
54. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP (1999) Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140:5828–40
55. Yang Z, He X, Zhang Y (2007) The determination of raloxifene in rat tissue using HPLC. Biomed Chromatogr 21:229–33
56. + channel inactivation by MEK inhibitor U0126. Am J Physiol Cell Physiol 290:C165–71
57. + current: characterization of open channel block. J Pharmacol Exp Ther 274:249–57